Rheumatic fever medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 24: Line 24:


Some patients develop significant [[carditis]] which manifests as [[congestive heart failure]]. This requires the usual treatment for heart failure which includes [[diuretics]], [[ACE inhibitors]] and [[digoxin]]. Unlike normal heart failure, rheumatic heart failure responds well to [[corticosteroids]]. [[Prednisone]] or [[prednisolone]] (1-2mg/kg/day) are the corticosteroids of choice with maximum dose being 80mg/day. The treatment with corticosteroids is usually for a period of 2-4 weeks after which the dose is tapered by 25% each week while maintaining high levels of [[salicylate]]s to minimize adverse effects.
Some patients develop significant [[carditis]] which manifests as [[congestive heart failure]]. This requires the usual treatment for heart failure which includes [[diuretics]], [[ACE inhibitors]] and [[digoxin]]. Unlike normal heart failure, rheumatic heart failure responds well to [[corticosteroids]]. [[Prednisone]] or [[prednisolone]] (1-2mg/kg/day) are the corticosteroids of choice with maximum dose being 80mg/day. The treatment with corticosteroids is usually for a period of 2-4 weeks after which the dose is tapered by 25% each week while maintaining high levels of [[salicylate]]s to minimize adverse effects.
===Valve defects===
Mitral regurgitation or stenosis may develop in patients with rheumatic fever. Patients with mild [[MR]] may remain asymptomatic, but should be followed regularly yearly. Patients with moderate [[MR]] should be assessed with echocardiogram yearly or when symptoms develop. Patients with severe [[MR]] should undergo serial echocardiographic studies every 6 to 12 months to assess left ventricular size and ejection fraction which is important for timing of surgery<ref name="pmid18820172">{{cite journal| author=Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, Freed MD et al.| title=2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. | journal=Circulation | year= 2008 | volume= 118 | issue= 15 | pages= e523-661 | pmid=18820172 | doi=10.1161/CIRCULATIONAHA.108.190748 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18820172  }} </ref>.


==National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand Treatment Guidelines<ref name="pmid17547548">{{cite journal| author=Carapetis JR, Brown A, Wilson NJ, Edwards KN, Rheumatic Fever Guidelines Writing Group| title=An Australian guideline for rheumatic fever and rheumatic heart disease: an abridged outline. | journal=Med J Aust | year= 2007 | volume= 186 | issue= 11 | pages= 581-6 | pmid=17547548 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17547548  }} </ref>==
==National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand Treatment Guidelines<ref name="pmid17547548">{{cite journal| author=Carapetis JR, Brown A, Wilson NJ, Edwards KN, Rheumatic Fever Guidelines Writing Group| title=An Australian guideline for rheumatic fever and rheumatic heart disease: an abridged outline. | journal=Med J Aust | year= 2007 | volume= 186 | issue= 11 | pages= 581-6 | pmid=17547548 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17547548  }} </ref>==

Revision as of 17:15, 3 November 2011

Rheumatic fever Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Rheumatic Fever from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Jones Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Rheumatic fever medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rheumatic fever medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rheumatic fever medical therapy

CDC on Rheumatic fever medical therapy

Rheumatic fever medical therapy in the news

Blogs on Rheumatic fever medical therapy

Directions to Hospitals Treating Rheumatic fever

Risk calculators and risk factors for Rheumatic fever medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Lance Christiansen, D.O.; Associate Editor(s)-in-Chief: Varun Kumar, M.B.B.S. [2]; Cafer Zorkun, M.D., Ph.D. [3]

Overview

The management of acute rheumatic fever is geared toward the reduction of inflammation with anti-inflammatory medications such as aspirin or corticosteroids. Individuals with positive cultures for strep throat should also be treated with antibiotics. Another important cornerstone in treating rheumatic fever includes the continuous use of low dose antibiotics (such as penicillin, sulfadiazine, or erythromycin) to prevent recurrence.

Treatment

Antibiotic treatment in patients with rheumatic fever is aimed at eradication of group A streptococcus from the body. Patients with positive cultures for streptococcus pyogenes and even those suspected to have strep infection should be treated with penicillin as long as allergy is not present. This treatment will not alter the course of the acute disease. Oral penicillin V is the drug of choice, but ampicillin and amoxicillin are equally effective. Intramuscular benzathine penicillin is an alternative when oral penicillin is not feasible. Patients allergic to penicillin should be treated with cephalosporin or erythromycin[1].

Infection control among patients with streptococcus pharyngitis should be managed as follows:

  • Hospitalized patients should be placed on droplet precautions and other standard precautions until 24hours after initiation of antibiotics.
  • People in contact with patients with streptococcus pharyngitis should undergo evaluation for infection and treatment if infected.
  • Infected children should not attend school or childcare until 24hours after initiation of antibiotics.

Arthritis/Arthralgia

Pain and inflammation in joints can be controlled with paracetamol or salicylates[2][3]. Mild arthalgia and fever may respond to paracetamol alone. If arthalgia is severe, high dose of aspirin can be used. But patient should be monitored for symptoms of salicylate toxicity such as tinnitus, headache, or hyperpnea. 20-30mg/100dL are desired serum levels and should be maintained until the signs and symptoms of acute rheumatic fever are resolved or residing.

Duration of treatment is usually 1-2weeks and may be extended if the symptoms persists. When discontinuing therapy, aspirin should be discontinued gradually over weeks to avoid rebound reaction.

Sydenham's chorea

Sydenham's chorea is usually self limiting, resolving within few weeks[4]. Long term antibiotic prophylaxis is indicated in patients with Sydenham's chorea even in the absence of other manifestations of rheumatic fever. Chorea aggravates with emotional stress and attenuates with sleep. Therefore it can be controlled by sedating the patient with diazepam or phenobarbital. In severe cases, patient should be placed at high risk of injury and treated with carbamazepine or valproic acid[5][6]. Anti-inflammatories such as glucocorticoids and aspirin have no effect on Sydenham's chorea[7].

Heart failure

Some patients develop significant carditis which manifests as congestive heart failure. This requires the usual treatment for heart failure which includes diuretics, ACE inhibitors and digoxin. Unlike normal heart failure, rheumatic heart failure responds well to corticosteroids. Prednisone or prednisolone (1-2mg/kg/day) are the corticosteroids of choice with maximum dose being 80mg/day. The treatment with corticosteroids is usually for a period of 2-4 weeks after which the dose is tapered by 25% each week while maintaining high levels of salicylates to minimize adverse effects.

Valve defects

Mitral regurgitation or stenosis may develop in patients with rheumatic fever. Patients with mild MR may remain asymptomatic, but should be followed regularly yearly. Patients with moderate MR should be assessed with echocardiogram yearly or when symptoms develop. Patients with severe MR should undergo serial echocardiographic studies every 6 to 12 months to assess left ventricular size and ejection fraction which is important for timing of surgery[1].

National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand Treatment Guidelines[8]

All cases

Single dose intramuscular benzathine penicillin G (preferable) or oral penicillin V for 10 days (intravenous penicillin not needed; oral erythromycin may be used if patient allergic to penicillin)

Arthritis and fever

Chorea

Carditis/heart failure

  • Bed-rest
  • Urgent echocardiogram
  • Anti-heart failure medication
  • Valve surgery for life-threatening acute carditis (rare)

Long-term preventive measures

  • Give first dose of secondary prophylaxis
  • Notify case for recording in ARF/RHD register, if available
  • Contact local health staff to ensure follow-up
  • Provide culturally appropriate education to patient and family
  • Arrange dental review and ongoing dental care to reduce risk of endocarditis

References

  1. 1.0 1.1 Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, Freed MD; et al. (2008). "2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Circulation. 118 (15): e523–661. doi:10.1161/CIRCULATIONAHA.108.190748. PMID 18820172.
  2. BYWATERS EG, THOMAS GT (1961). "Bed rest, salicylates, and steroid in rheumatic fever". Br Med J. 1 (5240): 1628–34. PMC 1954279. PMID 13689614.
  3. DORFMAN A, GROSS JI, LORINCZ AE (1961). "The treatment of acute rheumatic fever". Pediatrics. 27: 692–706. PMID 13723875.
  4. LESSOF MH, BYWATERS EG (1956). "The duration of chorea". Br Med J. 1 (4982): 1520–3. PMC 1980122. PMID 13316200.
  5. Peña J, Mora E, Cardozo J, Molina O, Montiel C (2002). "Comparison of the efficacy of carbamazepine, haloperidol and valproic acid in the treatment of children with Sydenham's chorea: clinical follow-up of 18 patients". Arq Neuropsiquiatr. 60 (2-B): 374–7. PMID 12131934.
  6. Genel F, Arslanoglu S, Uran N, Saylan B (2002). "Sydenham's chorea: clinical findings and comparison of the efficacies of sodium valproate and carbamazepine regimens". Brain Dev. 24 (2): 73–6. PMID 11891095.
  7. Markowitz, M. & Gordis, L., Rheumatic Fever, 2nd ed. 1972. W.B. Saunders: Philadelphia
  8. Carapetis JR, Brown A, Wilson NJ, Edwards KN, Rheumatic Fever Guidelines Writing Group (2007). "An Australian guideline for rheumatic fever and rheumatic heart disease: an abridged outline". Med J Aust. 186 (11): 581–6. PMID 17547548.

Template:WH Template:WS